Primary Tumor Standardized Uptake Value Measured on Fluorodeoxyglucose Positron Emission Tomography Is of Prognostic Value for Survival in Non-small Cell.

Slides:

Advertisements

Similar presentations

PUBLISH ONLY Journal of Thoracic Oncology

Advertisements

A Systematic Review and Meta-analysis of the Literature: Chemotherapy and Surgery versus Surgery Alone in Non-small Cell Lung Cancer Sarah Burdett, MSc,

Liver Metastasis Is Associated with Poor Progression-Free Survival in Patients with Non–Small Cell Lung Cancer Treated with Nivolumab Tomoko Funazo,

Lymphovascular Invasion as a Prognostic Indicator in Stage I Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis Nathan M. Mollberg, DO,

Chee Khoon Lee, PhD, Johnathan Man, M. B. B. S

Quantitative Analysis of Circulating Cell-Free DNA for Correlation with Lung Cancer Survival: A Systematic Review and Meta-Analysis Sarah Cargnin, PhD,

Prognostic Significance of the Number of Lymph Nodes Removed at Lobectomy in Stage IA Non-small Cell Lung Cancer Sai-Hong Ignatius Ou, MD, PhD, Jason.

Maintenance Sunitinib following Initial Platinum-Based Combination Chemotherapy in Advanced-Stage IIIB/IV Non–Small Cell Lung Cancer: A Randomized, Double-Blind,

Standard Uptake Value Predicts Survival in Non–Small Cell Lung Cancer

Utility of 18F-FDG PET for Predicting Histopathologic Response in Esophageal Carcinoma following Chemoradiation Andrea L.H. Arnett, MD, PhD, Kenneth.

Prognostic Significance of C-Reactive Protein and Smoking in Patients with Advanced Non-small Cell Lung Cancer Treated with First-Line Palliative Chemotherapy

Outcomes of Second-Line Chemotherapy in Patients with Relapsed Extensive Small Cell Lung Cancer Sandra Froeschl, MD, Garth Nicholas, MD, FRCPC, Victor.

Diagnostic Performance of Integrated Positron Emission Tomography/Computed Tomography for Mediastinal Lymph Node Staging in Non-small Cell Lung Cancer:

Nicolas Girard, MD, Julie Teruya-Feldstein, MD, Eden C

Complement and Correction for Meta-Analysis of Patients with Extensive-Stage Small Cell Lung Cancer Managed with Irinotecan/Cisplatin versus Etoposide/Cisplatin.

Primary Tumor Standardized Uptake Value (SUVmax) Measured on Fluorodeoxyglucose Positron Emission Tomography (FDG-PET) is of Prognostic Value for Survival.

Salvage Lung Resection After Definitive Radiation (>59 Gy) for Non-Small Cell Lung Cancer: Surgical and Oncologic Outcomes Julie E. Bauman, MD, Michael.

Ellen M. Schultz, MS, Gerard A. Silvestri, MD, MS, Michael K

Gemcitabine and Irinotecan for Patients with Untreated Extensive Stage Small Cell Lung Cancer: SWOG 0119 Wallace Akerley, MD, Jason McCoy, MS, Paul J.

Electronic Updates for JTO Readers

Adjuvant Cisplatin and Vinorelbine for Completely Resected Non-small Cell Lung Cancer: Subgroup Analysis of the Lung Adjuvant Cisplatin Evaluation Jean-Yves.

Diffusion-Weighted Magnetic Resonance Imaging for Diagnosing Malignant Pulmonary Nodules/Masses: Comparison with Positron Emission Tomography Takeshi.

Prognostic Value of Vascular Endothelial Growth Factor Expression in Patients with Lung Cancer: A Systematic Review with Meta-Analysis Ping Zhan, MD,

The International Association for the Study of Lung Cancer International Staging Project on Lung Cancer Peter Goldstraw, MB, FRCS, John J. Crowley, PhD

Samuel J. Wang, MD, PhD, C David Fuller, MD, Charles R. Thomas, MD

Frank Detterbeck, MD Journal of Thoracic Oncology

Central versus Peripheral Tumor Location: Influence on Survival, Local Control, and Toxicity Following Stereotactic Body Radiotherapy for Primary Non–Small-Cell.

Poor Prognosis Patients with Inoperable Locally Advanced NSCLC and Large Tumors Benefit from Palliative Chemoradiotherapy: A Subset Analysis from a Randomized.

Liver Metastasis Is Associated with Poor Progression-Free Survival in Patients with Non–Small Cell Lung Cancer Treated with Nivolumab Tomoko Funazo,

Survival Benefit of Neoadjuvant Chemotherapy in Non-small Cell Lung Cancer: An Updated Meta-Analysis of 13 Randomized Control Trials Wei-An Song, MD,

Meta-Analysis of First-Line Therapies in Advanced Non–Small-Cell Lung Cancer Harboring EGFR-Activating Mutations Benjamin Haaland, PhD, Pui San Tan,

An Updated Meta-Analysis of Randomized Controlled Trials Comparing Irinotecan/Platinum with Etoposide/Platinum in Patients with Previously Untreated.

Second-line or Subsequent Systemic Therapy for Recurrent or Progressive Non-Small Cell Lung Cancer: A Systematic Review and Practice Guideline J Noble,

Phase II Randomized Study of Two Regimens of Sequentially Administered Mitomycin C and Irinotecan in Patients with Unresectable Esophageal and Gastroesophageal.

Intratumoral Lymphatic Vessel Involvement is an Invasive Indicator of Completely Resected Pathologic Stage I Non-small Cell Lung Cancer Masahiko Harada,

Jeffrey Bradley, MD, Issam El Naqa, PhD Journal of Thoracic Oncology

Association between Congenital Lung Malformations and Lung Tumors in Children and Adults: A Systematic Review Arianna Casagrande, MD, Federica Pederiva,

Prophylactic Cranial Irradiation for Patients with Surgically Resected Small Cell Lung Cancer Jianlin Xu, MD, Haitang Yang, MD, Xiaolong Fu, MD, Bo Jin,

PUBLISH ONLY Journal of Thoracic Oncology

PD-L1 as a Companion Biomarker for Immune Checkpoint Inhibitors in NSCLC: Should RNA ISH (RISH) Be Considered? Steven G. Gray, PhD Journal of Thoracic.

Daniel Morgensztern, MD, Boone Goodgame, MD, Maria Q

Absence of a Relationship between Tumor 18F-fluorodeoxyglucose Standardized Uptake Value and Survival in Patients Treated with Definitive Radiotherapy.

Appropriateness of Surgical Approach in Black Patients with Lung Cancer—15 Years Later, Little Has Changed Emanuela Taioli, MD, PhD, Raja Flores, MD

Positron Emission Tomography 18F-Fluorodeoxyglucose Uptake and Prognosis in Patients with Surgically Treated, Stage I Non-small Cell Lung Cancer: A Systematic.

Prognostic Impact of Immune Microenvironment in Lung Squamous Cell Carcinoma Kyuichi Kadota, MD, PhD, Jun-ichi Nitadori, MD, PhD, Hideki Ujiie, MD, Daniel.

Preoperative versus Postoperative Chemotherapy in Patients with Resectable Non- small Cell Lung Cancer: Systematic Review and Indirect Comparison Meta-Analysis.

A Systematic Review of Restaging After Induction Therapy for Stage IIIa Lung Cancer: Prediction of Pathologic Stage Sara de Cabanyes Candela, MD, Frank.

Trends in Stage Distribution for Patients with Non-small Cell Lung Cancer: A National Cancer Database Survey Daniel Morgensztern, MD, Shean Huey Ng,

Gemcitabine in Brief versus Prolonged Low-Dose Infusion, both Combined with Cisplatin, for Advanced Non-small Cell Lung Cancer: A Randomized Phase II.

A Systematic Review and Meta-analysis of the Literature: Chemotherapy and Surgery versus Surgery Alone in Non-small Cell Lung Cancer Sarah Burdett, MSc,

Phase I Study of Lenalidomide in Solid Tumors

Maintenance Therapy and Advanced Non–Small-Cell Lung Cancer: A Skeptic's View Martin J. Edelman, MD, Thierry Le Chevalier, MD, Jean-Charles Soria, MD,

Jie Huang, Juan Peng, Linlang Guo, MD, PhD

Primary Tumor Standardized Uptake Value Measured on F18-Fluorodeoxyglucose Positron Emission Tomography Is of Prediction Value for Survival and Local.

Recursive Partitioning Analysis Groups II–III Brain Metastases of Non-small Cell Lung Cancer: A Phase II Randomized Study Comparing Two Concurrent Chemoradiotherapy.

Comparison of Docetaxel- and Vinca Alkaloid–Based Chemotherapy in the First-line Treatment of Advanced Non-small Cell Lung Cancer: A Meta-analysis of.

Marianna Koczywas, MD, Mihaela C. Cristea, MD

International Thymic Malignancies Interest Group: A Way Forward

European Lung Cancer Conference (ELCC) 2016 Organisation

Metastatic Lung Cancer to the Pancreas

Positron emission tomography predicts survival in malignant pleural mesothelioma Raja M. Flores, MD, Timothy Akhurst, MD, Mithat Gonen, PhD, Maureen Zakowski,

Wedge Resection for Non-small Cell Lung Cancer in Patients with Pulmonary Insufficiency: Prospective Ten-Year Survival John P. Griffin, MD, Charles E.

Tumor Lysis Syndrome in Limited-Stage Small-Cell Lung Cancer

Efficacy and Safety of Cisplatin/Pemetrexed Versus Cisplatin/Gemcitabine as First-Line Treatment in East Asian Patients with Advanced Non-small Cell Lung.

Impact of Information on Quality of Life and Satisfaction of Non-small Cell Lung Cancer Patients: A Randomized Study of Standardized versus Individualized.

18F-Fludeoxyglucose PET/CT in SCLC: Analysis of the CONVERT Randomized Controlled Trial Prakash Manoharan, MB ChB, Ahmed Salem, PhD, Hitesh Mistry, PhD,

Super Scan Using Positron Emission Tomography in Lung Cancer Patients

Concurrent Chemotherapy and Short Course Radiotherapy in Patients with Stage IIIA to IIIB Non-small Cell Lung Cancer Not Eligible for Radical Treatment:

Effect of Tumor Size on Prognosis in Patients Treated with Radical Radiotherapy or Chemoradiotherapy for Non–Small Cell Lung Cancer: An Analysis of the.

A Review of First-Line Treatment for Small-cell Lung Cancer

Presentation transcript:

Primary Tumor Standardized Uptake Value Measured on Fluorodeoxyglucose Positron Emission Tomography Is of Prognostic Value for Survival in Non-small Cell Lung Cancer: Update of a Systematic Review and Meta-Analysis by the European Lung Cancer Working Party for the International Association for the Study of Lung Cancer Staging Project Marianne Paesmans, MSc, Thierry Berghmans, MD, PhD, Michele Dusart, MD, Camillo Garcia, MD, Claude Hossein-Foucher, MD, PhD, Jean-Jacques Lafitte, MD, PhD, Céline Mascaux, MD, PhD, Anne-Pascale Meert, MD, PhD, Martine Roelandts, MD, Arnaud Scherpereel, MD, PhD, Vanessa Terrones Munoz, MD, Jean-Paul Sculier, MD, PhD Journal of Thoracic Oncology Volume 5, Issue 5, Pages 612-619 (May 2010) DOI: 10.1097/JTO.0b013e3181d0a4f5 Copyright © 2010 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 1 Funnel plot. Effect size: neperian logarithm of the hazard ratio. Journal of Thoracic Oncology 2010 5, 612-619DOI: (10.1097/JTO.0b013e3181d0a4f5) Copyright © 2010 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 2 Individual hazard ratios with their 95% confidence interval. Point estimates of individual hazard ratios with their 95% confidence interval on a logarithmic scale. By convention, HR >1 means that patients with a higher standard uptake value (SUV) on the primary tumor have a worse prognosis. Journal of Thoracic Oncology 2010 5, 612-619DOI: (10.1097/JTO.0b013e3181d0a4f5) Copyright © 2010 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 3 Combined HRs for survival results aggregation using different subsets of studies. Combined hazard ratios with 95% confidence intervals obtained from random-effects models. Journal of Thoracic Oncology 2010 5, 612-619DOI: (10.1097/JTO.0b013e3181d0a4f5) Copyright © 2010 International Association for the Study of Lung Cancer Terms and Conditions